Resistance of ERBB2 KD mutants to neratinib
Pathways in the Resistance of ERBB2 KD mutants to neratinib SuperPath
| # | Name | Source | Genes |
|---|---|---|---|
| 1 | Resistance of ERBB2 KD mutants to neratinib | Reactome | |
| 2 | Drug-mediated inhibition of ERBB2 signaling | Reactome | |
| 3 | Resistance of ERBB2 KD mutants to trastuzumab | Reactome | |
| 4 | Resistance of ERBB2 KD mutants to AEE788 | Reactome | |
| 5 | Drug resistance in ERBB2 KD mutants | Reactome | |
| 6 | Resistance of ERBB2 KD mutants to lapatinib | Reactome | |
| 7 | Resistance of ERBB2 KD mutants to tesevatinib | Reactome | |
| 8 | Resistance of ERBB2 KD mutants to sapitinib | Reactome | |
| 9 | Drug resistance in ERBB2 TMD/JMD mutants | Reactome | |
| 10 | Resistance of ERBB2 KD mutants to osimertinib | Reactome | |
| 11 | Resistance of ERBB2 KD mutants to afatinib | Reactome |
Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways
Disorders associated with Resistance of ERBB2 KD mutants to neratinib SuperPath
according to GeneCards Suite gene sharing
| # | Disorder | Type | Genes | Score |
|---|---|---|---|---|
| 1 | Paget disease, extramammary | Enrichment | ERBB2 | 3.53 |
| 2 | Visceral neuropathy, familial, 2, autosomal recessive | Enrichment | ERBB2 | 3.53 |
| 3 | Autosomal dominant combined immunodeficiency due to erbin deficiency | Enrichment | ERBIN | 3.53 |
| 4 | Serous carcinoma of the corpus uteri | Enrichment | ERBB2 | 3.53 |
| 5 | Barrett esophagus | Enrichment | ERBB2 | 2.93 |
| 6 | Glioma susceptibility 1 | Enrichment | ERBB2 | 2.63 |
| 7 | Lung non-small cell carcinoma | Enrichment | ERBB2 | 2.49 |
| 8 | Lung cancer susceptibility 3 | Enrichment | ERBB2 | 2.38 |
| 9 | Bladder cancer | Enrichment | ERBB2 | 2.07 |
| 10 | Hirschsprung disease 1 | Enrichment | ERBB2 | 2.07 |
| 11 | Lung cancer | Enrichment | ERBB2 | 2.03 |
| 12 | Gastric cancer | Enrichment | ERBB2 | 1.90 |
| 13 | Colorectal cancer | Enrichment | ERBB2 | 1.59 |
| 14 | Ovarian cancer | Enrichment | ERBB2 | 1.53 |
